RxDoctor Payments Data

Patricia Grant

Nurse Practitioner · Bay Shore, NYNPI 1629175609

Payments from drug & device makers

$1,917in general payments, 2019–2025

Across 95 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$251
  • Lundbeck LLC$232
  • Scilex Pharmaceuticals Inc.$230
  • Collegium Pharmaceutical, Inc.$176
  • Forte Bio-pharma LLC$164
  • Redhill Biopharma Inc.$128
  • plus $737 from 22 others

What the payments were for

  • Food & beverage$1,917100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,917 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$102,697
Medicare patients
112
Services billed
1,184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate103$44,804
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen729$29,009
Nucynta ErTapentadol Hcl20$27,098
Xtampza ErOxycodone Myristate39$21,874
Oxycodone Hcl779$15,748
LinzessLinaclotide25$15,683
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen479$15,190
BelbucaBuprenorphine Hcl16$9,424
OxycontinOxycodone Hcl13$5,906
Lidocaine44$5,710
Pregabalin230$4,500
Naloxone Hcl69$4,223
Buprenorphine20$4,030
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl18$3,742
Gabapentin338$3,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er, Belbuca$176$58,39675 claims
Redhill Biopharma Inc.Movantik$128$44,804103 claims
AbbVieLinzess$251$15,68325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Bay Shore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →